Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
4.000
+0.020 (0.50%)
Aug 15, 2025, 10:43 AM - Market open
Kezar Life Sciences Employees
Kezar Life Sciences had 55 employees as of December 31, 2024. The number of employees decreased by 3 or -5.17% compared to the previous year.
Employees
55
Change (1Y)
-3
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,287,109
Market Cap
29.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | -3 | -5.17% |
| Dec 31, 2023 | 58 | -26 | -30.95% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 9 | 19.15% |
| Dec 31, 2020 | 47 | 7 | 17.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KZR News
- 1 day ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire
- 2 months ago - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript) - Seeking Alpha
- 5 months ago - Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - Business Wire
- 5 months ago - Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - Business Wire
- 6 months ago - Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 - Business Wire